This promotional material is intended for UK Healthcare Professionals experienced in the diagnosis and treatment of psoriasis and psoriatic arthritis. SKYRIZI^®(risankizumab) and adalimumab prescribing information & adverse event reporting information can be found below.

SKYRIZI DOSING GUIDE

SKYRIZI PRESCRIBING INFORMATION

ADALIMUMAB PRESCRIBING INFORMATION

UK-RISN-230338. Date of preparation May 2024.

Contact us

Please complete the form below and a member of the SKYRIZI team will get back to you.

Please fill in your details below only if you are a UK registered healthcare professional and would like to request a meeting with an AbbVie representative.

First name*:

Please enter First name

Last name*:

Please enter Last name

E-mail address*:

E-mail address is not valid

Hospital name*:

Please enter Hospital name

Hospital postcode*:

Please enter Hospital postcode

Request a meeting with your local AbbVie representative

I consent to receive AbbVie Ltd communications about it‘s products, services, research, events, programmes and other information, including promotional content, that may be of interest to me using the information I provide. I may withdraw my consent at any time.

Please select one field.

Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

*Denotes mandatory field

Incorrect. Please try again

UK-SKZD-240027. Date of Preparation: May 2024

SKYRIZI PRESCRIBING INFORMATION
ADALIMUMAB PRESCRIBING INFORMATION

Contact us

Our therapy areas

Additional info

This website is for UK Healthcare Professionals only

Welcome